Yesterday, according to WWD, OneSkin, the peptide-focused skin care brand dedicated to healthy aging, has secured a $7 million Series A investment round, pushing its total funding to $20 million. The round, led by returning investor Selva Ventures, attracted participation from investors such as Plus Capital, Unilever Ventures, Able Partners, tech entrepreneur Kevin Rose, and Brazilian-American model, designer, and entrepreneur Camila Alves McConaughey, along with returning backers SOSV and Meta Planet. The oversubscribed round reflects growing investor confidence in OneSkin’s unique technology, proprietary OS-01 peptide, and science-driven approach to addressing skin aging at a cellular level.
Founded by scientists and Ph.D. holders Carolina Reis de Oliveira, Alessandra Zonari, Mariana Boroni, and Juliana Carvalho, OneSkin has developed a proprietary peptide that targets “zombie” or senescent cells, which accelerate skin aging. Through clinical studies conducted with third-party research partners, the brand has demonstrated that its OS-01 peptide can reverse signs of aging and enhance skin function. With the new funding, OneSkin plans to deepen its research into new peptide-based formulas and explore ingredient innovations to further advance their anti-aging technology.
Dr. Reis de Oliveira highlighted OneSkin’s commitment to remaining at the forefront of scientific advancement in skin care, saying, “We want to be the first to bring any advances in addressing aging with the most effective peptides.” This funding will also allow OneSkin to expand its team with seasoned professionals in marketing and operations, supporting the brand’s next phase of growth. Plans for increased distribution channels, particularly professional, are also in the works, though the company doesn’t foresee a move into physical retail in the immediate future.
